Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE versus COLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE versus COLOCORT.
CELESTONE vs COLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Colocort (hydrocortisone acetate) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune responses.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
10 mg rectally administered once daily, preferably at bedtime, as a retention enema.
None Documented
None Documented
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
Terminal elimination half-life: 2.5–3.5 hours (mean ~3 hours). No active metabolites, so duration of action correlates with half-life.
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Renal: ~30% as metabolites; fecal/biliary: ~20% as metabolites; remainder metabolized with minimal unchanged drug excreted.
Category C
Category C
Corticosteroid
Corticosteroid